Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting changes in director shareholdings and does not contain financial performance data.
Material Changes
On June 29, 2012, Non-Executive Directors were allocated notional Ordinary Shares at a price of £14.54 per share and notional American Depositary Shares (ADSs) at a price of $45.37 per ADS. These allocations covered the service period from April 1, 2012, to June 30, 2012. The Company and the directors were informed of these allocations on July 2, 2012.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly details compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director transactions.
Important Facts for Investors
- Transaction Type: Allocation of notional Ordinary Shares and ADSs to Non-Executive Directors.
- Allocation Date: June 29, 2012.
- Share Prices: Ordinary Shares at £14.54; ADSs at $45.37.
- Service Period: April 1, 2012, to June 30, 2012.
- Notification Date: July 2, 2012.
- Scope: Includes allocations for directors such as Sir Christopher Gent, Professor Sir Roy Anderson, and others listed in the filing.